Gemma Berenguera Risueño

Najeti SL (Najeti) is the Spanish venture capital arm of Najeti SAS in France, founded in 1994 by Thibaud Durand. The firm headquartered in Madrid, Spain with addition offices in France and the US.

Eco-Solution SA provides a platform that develops microorganisms for industrial environmental and regulatory requirements. Its directed in vivo evolution platform is based on the acceleration of natural evolution and requires no manipulation of the genome. Its bioconversion units developed by Eco-Solution employ advanced genetics and microorganisms to permit on-site disposal of hazardous industrial waste that is usually sent to incineration centers. The company was founded in 1999 and is headquartered in Romainville, France.

Arc Holdings SAS manufactures and distributes tableware products. Its products include plates, cutlery, cookware, dishes, glasses and other dining materials. The firm distributes products through different distributors and outlet stores. The company was founded in 1825 and is headquartered in Arques, France.

SpainCap operates as a non-profit organization.

The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.